



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2013

PART - I (₹ in lakhs), except share data Previous Year Year to date Quarter Ended figures Ended PARTICULARS SI. No 31/03/2013 31/12/2012 31/03/2012 31/03/2013 31-03-12 Audited Un-audited Audited Audited Audited Income from operations 7,470.36 (a) Net sales/income from operations (Net of excise duty) 6,239,48 6,289,42 25,788,46 20,420.78 (b) Other operating income Total income from operations (net) 7,470.36 6,239.48 6,289.42 25,788.46 20,420.78 Expenses a) Cost of materials consumed 2,634.47 2,364.64 2,487.22 8,827.40 8,145.56 b) Purchases of stock-in-trade c) Changes in inventories of finished goods, work-in-progress and 185.25 (773.81)418.09 (559.63)(564.74)stock-in-trade d) Employee benefits expense 554.62 768.53 633.69 2,537.70 2,283.03 e) Depreciation and amortisation expense 214.43 219.01 182.78 786.72 599.79 f) Other expenses - Manufacturing Exps 1,147.76 1,014.79 791.31 3,904.81 2,667.83 - Selling Exps 223.65 95.36 43.86 502.80 216.91 - Administrative Exps 409.34 264.22 446.39 1,787.50 1,704.57 929.72 - R & D Exps 982 12 821.77 3.469.32 3.304.91 89.38 348.06 - Provision for MTM on Forward contracts (26.07)(854.63)6,325.57 4.971.84 4.970.48 21,256.62 18,705.92 Total expenses Profit / (Loss) from operations before other income, finance 3 1,144.79 1,267.64 1,318.94 4,531.84 1,714.86 costs and exceptional items (1-2) 4 54.29 36.84 (148.59)104.34 190.25 Profit / (Loss) from ordinary activities before finance costs and 5 1,199.08 1,304.48 1,170.35 4,636.18 1,905.11 exceptional items (3 ± 4) 270.74 468.53 420.86 1,350.94 990.93 Profit / (Loss) from ordinary activities after finance costs but 7 928.34 835.95 749.49 3,285.24 914.18 before exceptional items (5 ± 6) Exceptional Items 8 835.95 3,285.24 914.18 9 Profit/Loss from Ordinary Activities before tax (7 ± 8) 928.34 749.49 10 Tax Expenses 65.30 60.27 34.91 201.29 (522.06)11 Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10) 863.04 775.68 714.58 3,083.95 1,436.24 12 Extraordinary Items (net of tax expense ₹ ____ Lakhs) Net Profit (+)/Loss(-) for the period (11 ± 12) 863.04 775.68 714.58 3,083.95 1,436.24 13 Share of profit / (loss) of associates* 15 Minority interest * _ _ _ Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) * 17 Paid-up equity share capital 1,168.29 1,167.32 1,167.32 1,168.29 1,167.32 (Face Value of the Share shall be indicated) Re.1.00 Re.1.00 Re.1.00 Re.1.00 Re.1.00 Reserve excluding Revaluation Reserves as per balance sheet of 14,277.69 11,584.83 previous accounting year Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised): a) Basic 0.74 0.66 0.61 1.23 2.64 0.74 0.66 0.61 2.64 1.23 Earning Per Share (EPS) (after extraordinary items) (of Rs. 1/-19.ii each) (not annualised): a) Basic 0.74 1.23 0.66 0.61 2.64 0.74 1.23 b) Diluted 0.66 0.61 2.64

PART - II								
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31-03-12		
Α	PARTICULARS OF SHAREHOLDING	Audited	Un-audited	Audited	Audited	Audited		
1	Public share holdings							
	- Number of shares	41,993,960	42,679,160	42,679,160	41,993,960	42,679,160		
	- Percentage of Share holding	35.94%	36.56%	36.56%	35.94%	36.56%		
2	Promoters and promoter group Shareholding**							
	a) Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL		
	- Number of shares							
	- Percentage of Shares (as a $\%$ of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL		
	- Percentage of shares (as a $\%$ of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL		
	b) Non-Encumbered	74,834,828	74,052,828	74,052,828	74,834,828	74,052,828		
	- Number of shares							
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%		
	- Percentage of shares (as a $\%$ of the total share capital of the company)	64.06%	63.44%	63.44%	64.06%	63.44%		
	Particulars 3 months ended (31/03/2013)							
В	INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter	0						
	Received during the quarter	27						
	Disposed of during the quarter	27						
	Remaining unresolved at the end of the quarter	0						

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							
	PARTICULARS	Year					
		0.1.100.100.10	Quarter Ended	figures	Year Ended		
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31-03-12	
		Audited	Un-audited	Audited	Audited	Audited	
1	SEGMENT REVENUE :-						
	a) Manufaturing (CRAMS)	6,484.41	5,402.01	5,893.92	22,760.54	19,168.87	
	b) Services	985.96	837.46	367.88	3,027.92	1,251.91	
	c) Research & Development	-	-	-	-	-	
	Net Sales from Operations	7,470.37	6,239.47	6,261.80	25,788.46	20,420.78	
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
	a) Manufaturing (CRAMS)	2,112.34	1,904.71	1,708.87	7,928.86	6,507.91	
	b) Services	258.94	618.02	72.38	1,514.45	531.83	
	c) Research & Development	(982.12)	(929.72)	(821.77)	(3,469.32)	(3,304.91)	
	TOTAL	1,389.16	1,593.01	959.48	5,973.99	3,734.83	
Less:	i) Interest	172.97	441.82	318.43	1,174.34	888.50	
	ii) Other Un-allocable exps net off un-allocable Income	287.84	315.24	(108.44)	1,514.40	1,932.15	
	Total Profit Before Tax	928.35	835.95	749.49	3,285.25	914.18	
3	CAPITAL EMPLOYED						
	(Segment Assets - Segment Liabilities)						
	a) Manufaturing (CRAMS)	12,823.28	13,053.17	10,704.10	12,823.28	10,704.10	
	b) Services	3,053.52	3,035.70	3,298.34	3,053.52	3,298.34	
	c) Research & Development	2,412.64	2,157.59	2,228.26	2,412.64	2,228.26	
	d) Net assets which are not segmented and used commonly	3,574.87	4,237.93	2,023.90	3,574.87	2,023.90	
	TOTAL	21,864.31	22,484.39	18,254.60	21,864.31	18,254.60	

Notes: 1) The above audited results were approved and taken on record at the Board of Directors' meeting held on 14th May '13

- 2) Previous years figures have been regrouped / reclassified whenever necessary.
- 3) The figures of the last quarter are the balancing figures between audited figures inrespect of full year and un-audited declared upto 3rd quarter ending.
- 4) Suven Nishtaa Pharma Pvt Ltd, the 100% subsiadary, has been merged w.e.f. 1st Jan 2012. Hence the current year's figures are not comparable with the previous year figures.
- 5) The Board has recommended a Dividend of Re.0.30 per Equity share (i.e.30% of face value of Rs.1/- each) for the year 2012-13, subject to approval of the shareholders in the ensuing Annual General Meeting.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad VENKAT JASTI
Date: 14th May 2013 Chairman & CEO

We Deliver